The British Government has accepted all 44 recommendations from an independent commission on regulating AI in healthcare. Its 6 October announcement, issued by the Department of Health and the Medicines and Healthcare products Regulatory Agency (MHRA), promises proportionate regulation, post-market monitoring and clearer coordination between institutions. The response also opens a third phase of AI Airlock, the MHRA’s regulatory sandbox for AI medical devices. The news matters because it moves the debate beyond initial approval towards what happens when a product is updated, changes hospital or meets a different patient population. Source: UK Government / MHRA Source: UK Government / MHRA
The recommendations came from a commission established by the MHRA in 2025. Its report, published on 10 September, followed a year of UK-wide engagement and collected evidence from more than 12,000 people, according to the administration. The official response includes a table explaining how each recommendation will be addressed and sets ten priority areas for work with governments, the NHS, regulators and devolved authorities. The scope is broad: evidence standards, patient safety, monitoring in use, clear responsibilities and public involvement. Accepting the package sets a political direction; it does not automatically turn every proposal into a legal duty the next day.
The timetable makes the distance between endorsement and execution clear. The Government plans to publish draft guidance in December on adaptive changes to medical devices using AI. It has announced later consultations on classification and qualification and a full roadmap for spring 2027. AI Airlock Phase 3 will run for three years, accept applications and select its first cohort of innovators in November. The programme aims to bring manufacturers, regulators and health providers together to understand practical obstacles and the monitoring of real products. It is a regulatory laboratory: it can generate learning for rulemaking, but it does not replace safety assessment or certify every product that takes part.
Medical software presents a particular regulatory problem: the object assessed may not be the object a clinician eventually uses. An update can improve sensitivity, alter false-positive rates or change which patients receive a recommendation. If a version changes after approval, the question is no longer simply whether the original algorithm worked. Regulators also need to know which changes are permissible, what evidence must be submitted, who monitors real-world performance and how to respond when results diverge from trials. A lifecycle approach aims to answer that sequence. Its effectiveness will depend on useful data from hospitals and manufacturers and on whether regulators can intervene quickly.
The announcement includes questions of legitimacy that often disappear beneath the word ‘innovation’. The response refers to stronger patient involvement, clear routes to redress when something goes wrong and monitoring technology in use. These are practical requirements: a system may improve an average while harming a subgroup; a device that worked in a trial may perform worse in a network with different equipment, languages and protocols. Post-market monitoring may detect a difference that was invisible before release. Someone must collect incidents, compare them with the authorised conditions and publish what action followed.
The package’s political promise is to speed access without shifting risk onto patients and staff. That requires defining sufficient evidence, controlling model changes and identifying which institution answers when responsibility is divided among a developer, hospital and cloud provider. The Commission called for institutional coordination, and the Government says a Programme Board will bring together the MHRA, NHS, ministries and territorial authorities. A board can reduce gaps; its name alone does not settle who has the power, budget and duty to act on an early signal of harm.
For a patient, ‘we accepted all 44 recommendations’ will matter only when it becomes access to understandable information, a route to complain and ongoing evaluation of outcomes. For the sector, the timetable matters because unpredictable rules raise the cost of investment and deployment; late regulation leaves uncertainty to be resolved in the consulting room or in the patient’s body. Britain has put an agenda and implementation dates on the table. The test is whether it turns the commitment into verifiable standards, adequately resourced monitoring and public decisions when evidence contradicts a commercial promise.